drugset / Trial / NCT00995085

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

NCT00995085

Phase 1 Completed 43 enrolled Alcobra Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD. Study also assess cognitive effects of such drug administration.

Timeline

Start
2009-10
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Metadoxine Unknown 1400 mg Oral